View Older Stories View More Recent Stories

Jun 27, 2016 06:28AM Merck (MRK) Announces Receipt of Positive CHMP Opinion on KEYTRUDA as NSCLC Treatment
Jun 27, 2016 06:00AM Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Jun 24, 2016 08:00AM Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
Jun 22, 2016 04:36PM Incyte (INCY) Treats First Patient in ECHO-301 Combo Phase 3 (MRK)
Jun 20, 2016 12:35PM Merck (MRK) Announces Relebactam Combo Phase 2 Met Primary Endpoint
Jun 20, 2016 12:30PM Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Jun 16, 2016 08:00AM Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
Jun 16, 2016 06:46AM Merck (MRK) Announces Superior Data on KEYTRUDA vs. Chemotherapy in Untreated NSCLC
Jun 16, 2016 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Jun 15, 2016 08:30AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
Jun 13, 2016 10:31AM Merck (MRK) Announces MK-1293 Met Primary Endpoint in Two Phase 3 Studies
Jun 13, 2016 10:30AM Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Jun 11, 2016 11:00AM Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
Jun 9, 2016 06:34PM Merck to Acquire Afferent Pharmaceuticals
Jun 9, 2016 05:08PM Merck (MRK) Enters Agreement to Acquire Afferent Pharma in ~$1.25B Deal
Jun 9, 2016 05:07PM Merck to Acquire Afferent Pharmaceuticals
Jun 6, 2016 08:00AM Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent
Jun 6, 2016 08:00AM KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
Jun 6, 2016 06:35AM Merck (MRK) Announces Presentation of New KEYTRUDA Data in NSCLC
Jun 5, 2016 01:43PM New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
Jun 5, 2016 08:00AM New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Jun 4, 2016 08:00AM New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Jun 4, 2016 08:00AM New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Jun 1, 2016 05:00PM Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
May 27, 2016 07:47AM Merck (MRK) Announces Positive CHMP Opinion for ZEPATIER
May 27, 2016 07:46AM Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union
May 24, 2016 02:35PM Merck Announces Third-Quarter 2016 Dividend
May 24, 2016 08:00AM Merck to Present at the UBS Global Healthcare Conference
May 18, 2016 05:20PM Merck (MRK) Plans KEYTRUDA, KEYNOTE-006 and KEYNOTE-001 Presentations at ASCO 2016
May 18, 2016 05:19PM New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
May 16, 2016 08:02AM Merck (MRK) Will Present New KEYTRUDA Data in Head and Neck Cancer, NSCLC
May 16, 2016 08:00AM New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated
May 12, 2016 08:32AM Merck (MRK) Will Present JANUVIA, Diabetes Pipeline, Other Data at 76th Scientific Sessions of the ADA
May 12, 2016 08:30AM Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association
May 5, 2016 06:45AM Merck Announces First-Quarter 2016 Financial Results
May 4, 2016 08:00AM Merck to Present at the Deutsche Bank 41st Annual Health Care Conference
Apr 28, 2016 08:00AM Christina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They're So Awake"
Apr 27, 2016 08:00AM Merck, the American Diabetes Association and America's Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic
Apr 26, 2016 11:39AM Journal of the American Medical Association Publishes Phase III Data from Allergic Asthma Trial with ALK's House Dust Mite SLIT-tablet, ACARIZAX®
Apr 19, 2016 05:01PM Merck (MRK) Animal Health Enters Agreement to Acquire Whisper Veterinary Stethoscope System
Apr 19, 2016 05:00PM Merck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System
Apr 19, 2016 02:08PM Merck (MRK) Comments on Blueprint PD-L1 Assay Comparison Project; Encouraged by Findings
Apr 19, 2016 02:05PM Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
Apr 18, 2016 08:05AM Merck (MRK) Receives FDA Breakthrough Therapy Designation for KEYTRUDA in cHL
Apr 18, 2016 08:00AM Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
Apr 18, 2016 06:51AM Merck (MRK) Preents Data from Two ZEPATIER Phase 3s; High SVR Demonstrated
Apr 16, 2016 01:00AM Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Apr 14, 2016 06:22AM Merck (MRK) Announces Strong Data from C-EDGE Head-to-Head Study
Apr 14, 2016 01:00AM Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Apr 13, 2016 07:01AM Merck (MRK) Announces FDA Acceptance of KEYTRUDA sBLA; Priority Review Granted
View More Recent Stories View Older Stories